Companies /Healthcare
Alkermes plc
NASDAQ: ALKS Drug Manufacturers - Specialty & Generic
$45.69
▲ $0.80 (+1.78%) today
Markets closed · 3:49am ET

Alkermes (ALKS) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
29%
EPS beat rate
−154.41%
Avg. EPS surprise
Consecutive EPS misses
ALKS vs Market · 30-day return after each reportALKSS&P 500
−8%0%+8%+16%+2.3%+6.7%Q1 25+7.2%+2.2%Q2 25−4.6%−0.5%Q3 25−5.3%−8.5%Q4 25+18.1%+1.9%Q1 26−3.2%+4.1%Q2 26
−8%0%+8%+16%Q1 25Q3 25Q1 26
ALKS EPS Trend · estimate vs actualEstimateActual
$-0.30$0.00$0.30$0.24$0.13Q1 25$0.38$0.52Q2 25$0.39$0.49Q3 25$0.45$0.29Q4 25$-0.04$-0.40Q1 26$0.29$0.00Q2 26$0.25$0.09Q3 26
$-0.30$0.00$0.30Q1 25Q3 25Q1 26Q3 26
ALKS Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$304.1M$306.5MQ1 25$341.3M$390.7MQ2 25$356.2M$394.2MQ3 25$381.5M$384.5MQ4 25$361.4M$392.9MQ1 26$457.4M$496.0MQ2 26$464.9M$480.1MQ3 26
$0$200.0M$400.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Alkermes Beat Earnings Estimates?

Alkermes beat EPS estimates in 2 of its last 7 reported quarters, and has missed 4 quarters in a row.

ALKS quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 GAAP diluted EPS includes $29.8 million of costs related to the acquisition of Avadel (including $28.7 million in cost of goods sold, largely LUMRYZ inventory fair value step-up), $19.7 million amortization of acquired intangible assets, $27.6 million interest expense on acquisition debt, $0.6 million change in fair value of contingent consideration, and a $1.55 million income tax benefit $0.09 est. $0.25 −63.55% $480.1M est. $464.9M +3.27%
Q2 2026 $0.00 est. $0.29 −100.00% $496.0M est. $457.4M +8.45%
Q1 2026 $-0.40 est. $-0.04 −900.00% $392.9M est. $361.4M +8.73%
Q4 2025 $0.29 est. $0.45 −35.28% $384.5M est. $381.5M +0.80%
Q3 2025 $0.49 est. $0.39 +26.91% $394.2M est. $356.2M +10.66%
Q2 2025 $0.52 est. $0.38 +37.93% $390.7M est. $341.3M +14.46%
Q1 2025 $0.13 est. $0.24 −46.90% $306.5M est. $304.1M +0.79%

Figures from SEC filings and company reports. Not investment advice.